Pharma Focus Europe

GSK Opts to License Elsie Biotechnologies’ Discovery Platform for Novel Oligonucleotide Research and Development

Wednesday, February 14, 2024

Elsie Biotechnologies, Inc. made an announcement today that GSK plc (LSE/NYSE: GSK) has exercised its option for a non-exclusive license to Elsie’s discovery platform. This decision follows a successful research collaboration initiated in July 2023, aimed at exploring the platform's capabilities. This option grants GSK the ability to utilize Elsie’s discovery platform and P(V) chemistry technologies in its own oligonucleotide drug discovery research.

Elsie Biotechnologies, expressed satisfaction with GSK's decision to license their platform technology after the fruitful research collaboration. Green stated, "We are pleased that GSK has elected to license our platform technology following the research collaboration. GSK is a great innovator in the field of oligonucleotide therapeutics, and this license validates the potential of our discovery platform, which we believe can power next-generation RNA medicines, optimized for safety, activity, and delivery.”

GSK, conveyed excitement about the continued partnership with Elsie, emphasizing its alignment with GSK's focus at the intersection of science and technology. Donahue remarked, “We are excited to continue our work with Elsie which aligns so closely with our focus at the intersection of science and tech. It builds on our industry-leading position in advanced platform technologies and exemplifies our commitment to the potential of oligonucleotide therapeutics.”

Elsie’s discovery platform stands out as an unparalleled ultra-high throughput proprietary process enabling the comprehensive evaluation of oligonucleotide chemical space. Through the application of proprietary encoding technology to oligonucleotide therapeutic candidates, all possible sequences or chemical modification patterns can be assessed to enhance activity, reduce toxicity, and improve delivery. Additionally, Elsie employs proprietary P(V) chemistry technologies, including a suite of novel reagents and processes, to synthesize diverse oligonucleotide therapeutics with complete synthetic control.

As per the terms of the agreement, Elsie will receive a license payment from GSK and may potentially earn additional development and commercial milestones on a target-specific basis.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva